Morgan Stanley Schedule 13G passive stakes

Morgan Stanley and its wholly-owned subsidiary, Parametric Portfolio Associates LLC, have disclosed a combined 11.4% beneficial ownership stake in BrandywineGLOBAL-Global Income Opportunities Fund Inc.

Morgan Stanley and its wholly-owned subsidiary, Parametric Portfolio Associates LLC, have jointly disclosed a passive beneficial ownership of 5.1% in BlackRock Enhanced Global Dividend Trust, totaling 2,891,173 common shares.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, have filed an amended Schedule 13G, disclosing a beneficial ownership of 13.0% in BlackRock 2037 Municipal Target Term Trust.

Morgan Stanley and its subsidiaries have reported an aggregate beneficial ownership of 9.2% of Blackbaud Inc.'s common stock, held for ordinary business purposes.

Morgan Stanley has filed an amended Schedule 13G, disclosing that its beneficial ownership in Beyond, Inc. has decreased to 3.5% of common stock, falling below the 5% reporting threshold.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have reported a reduction in their beneficial ownership of AudioCodes Ltd. ordinary shares, falling below the 5% reporting threshold.

Morgan Stanley has filed an amended Schedule 13G, reporting a 6.3% beneficial ownership stake in Aramark's common stock as of March 31, 2025.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, have disclosed a passive 5.0% beneficial ownership stake in Allspring Utilities & High Income Fund.

Morgan Stanley and its wholly-owned subsidiary, Morgan Stanley Investment Management Inc., have filed an amended Schedule 13G disclosing a combined beneficial ownership of 12.2% of agilon health, Inc.'s common stock as of March 31, 2025.

Morgan Stanley and its wholly-owned subsidiary, Parametric Portfolio Associates LLC, have filed an amendment to their Schedule 13G, disclosing a combined beneficial ownership of 9.5% in abrdn Total Dynamic Dividend Fund.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, have disclosed beneficial ownership of 5.7% of abrdn Global Infrastructure Income Fund's common shares in a recent SEC Schedule 13G filing.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have reported a reduction in their beneficial ownership of Playa Hotels & Resorts N.V. ordinary shares, falling below the 5% reporting threshold.

Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., have disclosed a combined beneficial ownership of 10.1% of Aurora Innovation, Inc.'s Class A Common Stock as of March 31, 2025, held for passive investment purposes.

Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., have reported a reduction in their beneficial ownership of Peloton Interactive, Inc. Class A Common Stock, falling below the 5% reporting threshold.

Morgan Stanley has filed an amended Schedule 13G, indicating its beneficial ownership in Pharming Group N.V. has decreased to 1.2% as of March 31, 2025, falling below the 5% reporting threshold.

Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., have jointly filed a Schedule 13G, reporting a significant beneficial ownership stake of 10.0% in LandBridge Co LLC's Class A Shares.

Morgan Stanley has filed an amended Schedule 13G, disclosing that its beneficial ownership in Net Lease Office Properties has fallen below the 5% threshold.

Morgan Stanley and its subsidiary, Morgan Stanley & Co. LLC, have filed an amended Schedule 13G indicating they are no longer beneficial owners of more than five percent of Sage Therapeutics, Inc.'s common stock.

Morgan Stanley and its subsidiary, Morgan Stanley & Co. LLC, have reported ceasing to be beneficial owners of more than five percent of Marinus Pharmaceuticals, Inc.'s common stock as of February 28, 2025.

Morgan Stanley has filed an amended Schedule 13G, revealing a 5.0% beneficial ownership stake in Theratechnologies Inc. as of December 31, 2024.

Morgan Stanley and its subsidiary have filed an amended Schedule 13G, indicating they are no longer beneficial owners of more than five percent of Applied Therapeutics, Inc.'s common stock.

Morgan Stanley, along with its affiliates Atlanta Capital Management Company, LLC and Eaton Vance Atlanta Capital SMID-Cap Fund, has disclosed beneficial ownership of 8.2% of Envista Holdings Corp's common stock as of December 31, 2024.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have reported beneficial ownership of 5.8% of TAL Education Group's Class A Common Shares as of December 31, 2024.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, have filed an amended Schedule 13G indicating they are no longer beneficial owners of more than five percent of Virtus Total Return Fund Inc.'s common shares.

Morgan Stanley and its affiliates, including Calvert Research and Management and Calvert Impact Fund, Inc. Calvert Small-Cap Fund, have filed an amended Schedule 13G disclosing their beneficial ownership in U.S. Physical Therapy Inc., with Morgan Stanley holding 5.9% while the Calvert entities have reduced their stakes below the 5% threshold.

Morgan Stanley has filed an amended Schedule 13G, indicating it has ceased to be a beneficial owner of more than five percent of Sphere Entertainment Co.'s Class A Common Stock.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, have filed an amended Schedule 13G indicating their beneficial ownership in Cohen & Steers Real Estate Opportunities & Income Fund has fallen to 4.1%.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, have reported ceasing to be beneficial owners of more than five percent of the Common Shares of Beneficial Interest in Western Asset Inflation-Linked Opportunities & Income Fund.

Morgan Stanley and its wholly-owned subsidiary, Parametric Portfolio Associates LLC, have filed an amended Schedule 13G disclosing a combined beneficial ownership of 7.4% in Western Asset Inflation-Linked Opportunities & Income Fund.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have disclosed beneficial ownership of 8.6% and 7.0% respectively, of Taysha Gene Therapies, Inc.'s common stock as of December 31, 2024.